tbuckley/cabot-search huggingface dataset:
A TLR4‐Targeting Bioactive Peptide Hydrogel to Regulate Immune‐Microenvironment for Diabetic Wound Repair
Authors: Chuanjiang Jian, Minjia Wang, Yunyun Qian, Xuejiao Song, Li Wang, Ling Li, Lulu Huang, Guan Wang, Xianjie Shi, Jinqiao Dong, Hao Li, Ang Lin, Leilei Shi
Journal: Advanced Healthcare Materials (2024)

Abstract Persistent inflammation and disrupted immunoregulation are critical factors in impeding diabetic wound healing. While immunoregulatory hydrogel dressings hold significant promise for clinical applications in diabetic wound healing, the current application often demands intricate interventions and high‐cost treatments involving cytokines and cell therapies. The development of single component immunoregulatory hydrogels remains a complex challenge. To address this issue, an active peptide hydrogel with immunoregulatory properties targeting the TLR4/NF‐kB pathway, aiming to promote rapid diabetic wound healing, is engineered. The hydrogel sequence comprises naphthalene derivative, phenylalanine, and glycine to modulate hydrophilic/hydrophobic characteristics. The amino group on arginine contributes to tissue adhesion and regulation of intermolecular forces, ultimately yielding stable gels. The results underscore the formation of the peptide hydrogel (NFA) via the physical crosslinking of self‐assembled nanofibers in water, thereby affording both excellent injectability and tissue adhesion. Notably, NFA demonstrates significant potential in promoting wound healing in a mouse model with full‐thickness wounds by regulating macrophage responses in the inflammatory microenvironment through the TLR4/NF‐kB pathway.
Risk of Cardiac Arrhythmias Among Climbers on Mount Everest
Authors: Kunjang Sherpa, Pasang Phurba Sherpa, Tendi Sherpa, Martina Rothenbühler, Christoph Ryffel, Dhukpa Sherpa, Dawa Renji Sherpa, Ojaswee Sherchand, Oskar Galuszka, Chrisoula Dernektsi, Tobias Reichlin, Thomas Pilgrim
Journal: JAMA Cardiology (2024)

Importance Arterial hypoxemia, electrolyte imbalances, and periodic breathing increase the vulnerability to cardiac arrhythmia at altitude. Objective To explore the incidence of tachyarrhythmias and bradyarrhythmias in healthy individuals at high altitudes. Design, Setting, and Participants This prospective cohort study involved healthy individuals at altitude (8849 m) on Mount Everest, Nepal. Recruitment occurred from January 25 to May 9, 2023, and data analysis took place from June to July 2023. Exposure All study participants underwent 12-lead electrocardiogram, transthoracic echocardiography, and exercise stress testing before and ambulatory rhythm recording both before and during the expedition. Main Outcome The incidence of a composite of supraventricular (&amp;amp;gt;30 seconds) and ventricular (&amp;amp;gt;3 beats) tachyarrhythmia and bradyarrhythmia (sinoatrial arrest, second- or third-degree atrioventricular block). Results Of the 41 individuals recruited, 100% were male, and the mean (SD) age was 33.6 (8.9) years. On baseline investigations, there were no signs of exertional ischemia, wall motion abnormality, or cardiac arrhythmia in any of the participants. Among 34 individuals reaching basecamp at 5300 m, 32 participants climbed to 7900 m or higher, and 14 reached the summit of Mount Everest. A total of 45 primary end point–relevant events were recorded in 13 individuals (38.2%). Forty-three bradyarrhythmic events were documented in 13 individuals (38.2%) and 2 ventricular tachycardias in 2 individuals (5.9%). Nine arrhythmias (20%) in 5 participants occurred when climbers were using supplemental bottled oxygen, whereas 36 events (80%) in 11 participants occurred at lower altitudes when no supplemental bottled oxygen was used. The proportion of individuals with arrhythmia remained stable across levels of increasing altitude, while event rates per 24 hours numerically increased between 5300 m (0.16 per 24 hours) and 7300 m (0.37 per 24 hours) before decreasing again at higher altitudes, where supplemental oxygen was used. None of the study participants reported dizziness or syncope. Conclusion and Relevance In this study, more than 1 in 3 healthy individuals experienced cardiac arrhythmia during the climb of Mount Everest, thereby confirming the association between exposure to high altitude and incidence of cardiac arrhythmia. Future studies should explore the potential implications of these rhythm disturbances.
Human Leukocyte Antigens and Sulfamethoxazole/Cotrimoxazole–Induced Severe Cutaneous Adverse Reactions
Authors: Po-Chien Wu, Wei-Ti Chen, I-Hsin Huang, Chun-Bing Chen, Chuang-Wei Wang, Cheng-Chen Tai, Wen-Hung Chung, Ching-Chi Chi
Journal: JAMA Dermatology (2024)

Importance Sulfamethoxazole (SMX) and cotrimoxazole (CTX), a fixed-dose combination of SMX and trimethoprim in a 5:1 ratio, are antibacterial sulfonamides commonly used for treating various diseases. A substantial prevalence of severe cutaneous adverse reactions (SCARs) following the administration of these drugs has been reported. However, the association between human leukocyte antigen (HLA) genotypes and SMX/CTX-induced SCARs has remained unclear. Objective To investigate the association between HLA genotypes and SMX/CTX-induced SCARs. Data sources A comprehensive search was conducted in CENTRAL (Cochrane Library), MEDLINE, and Embase from inception to January 17, 2023. Study Selection Case-control studies that recruited patients who had experienced SCARs following SMX or CTX were included, and HLA alleles were analyzed. Data Extraction and Synthesis Two independent authors extracted data on study characteristics and outcome data. The Meta-analysis of Observational Studies in Epidemiology ( MOOSE ) reporting guideline and the Preferred Reporting Items for Systematic Reviews and Meta-analyses ( PRISMA ) reporting guidelines were followed. The Newcastle-Ottawa Scale for case-control studies was used to assess study quality. Odds ratios (ORs) were calculated using a random-effects model for meta-analysis. Main Outcomes and Measures The prespecified outcome was the OR comparing SMX/CTX-induced SCARs with healthy or SMX/CTX-tolerant controls based on different HLA alleles. Results Six studies involving 322 patients with SCAR were included, including 236 patients with Stevens-Johnson syndrome/toxic epidermal necrolysis, 86 with drug reaction with eosinophilia and systemic symptoms, 8448 healthy controls, and 229 tolerant controls. Significant associations were found in HLA-A*11:01 (OR, 2.10; 95% CI, 1.11-4.00), HLA-B*13:01 (OR, 5.96; 95% CI, 1.58-22.56), HLA-B*15:02 (OR, 2.23; 95% CI, 1.20-4.14), HLA-B*38:02 (OR, 3.47; 95% CI, 1.42-8.48), and HLA-C*08:01 (OR, 2.63; 95% CI, 1.07-6.44) compared with tolerant controls. In the Stevens-Johnson syndrome/toxic epidermal necrolysis subgroup, significant associations were found in HLA-B*15:02 (OR, 3.01; 95% CI, 1.56-5.80) and HLA-B*38:02 (OR, 5.13; 95% CI, 1.96-13.47). In the drug reaction with eosinophilia and systemic symptoms subgroup, significant associations were found in HLA-A*68:01 (OR, 12.86; 95% CI, 1.09-151.34), HLA-B*13:01 (OR, 23.09; 95% CI, 3.31-161.00), HLA-B*39:01 (OR, 4.56; 95% CI, 1.31-15.82). Conclusions and Relevance The results of this systematic review and meta-analysis suggest that multiple HLA alleles ( HLA-A*11:01 , HLA-B*13:01, HLA-B*15:02, HLA-B*38:02, and HLA-C*0801 ) are associated with SMX/CTX-induced SCARs.
Normothermic Regional Perfusion to Expand Liver Transplant From Controlled Donation After Circulatory Death
Authors: Laura Llado
Journal: JAMA Surgery (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Public Health Interventions and Overdose-Related Outcomes Among Persons With Opioid Use Disorder
Authors: Nisha Nataraj, S. Michaela Rikard, Kun Zhang, Xinyi Jiang, Gery P. Guy, Ketra Rice, Christine L. Mattson, R. Matthew Gladden, Desiree M. Mustaquim, Zachary N. Illg, Puja Seth, Rita K. Noonan, Jan L. Losby
Journal: JAMA Network Open (2024)

Importance Given the high number of opioid overdose deaths in the US and the complex epidemiology of opioid use disorder (OUD), systems models can serve as a tool to identify opportunities for public health interventions. Objective To estimate the projected 3-year association between public health interventions and opioid overdose-related outcomes among persons with OUD. Design, Setting, and Participants This decision analytical model used a simulation model of the estimated US population aged 12 years and older with OUD that was developed and analyzed between January 2019 and December 2023. The model was parameterized and calibrated using 2019 to 2020 data and used to estimate the relative change in outcomes associated with simulated public health interventions implemented between 2021 and 2023. Main Outcomes and Measures Projected OUD and medications for OUD (MOUD) prevalence in 2023 and number of nonfatal and fatal opioid-involved overdoses among persons with OUD between 2021 and 2023. Results In a baseline scenario assuming parameters calibrated using 2019 to 2020 data remained constant, the model projected more than 16 million persons with OUD not receiving MOUD treatment and nearly 1.7 million persons receiving MOUD treatment in 2023. Additionally, the model projected over 5 million nonfatal and over 145 000 fatal opioid-involved overdoses among persons with OUD between 2021 and 2023. When simulating combinations of interventions that involved reducing overdose rates by 50%, the model projected decreases of up to 35.2% in nonfatal and 36.6% in fatal opioid-involved overdoses among persons with OUD. Interventions specific to persons with OUD not currently receiving MOUD treatment demonstrated the greatest reduction in numbers of nonfatal and fatal overdoses. Combinations of interventions that increased MOUD initiation and decreased OUD recurrence were projected to reduce OUD prevalence by up to 23.4%, increase MOUD prevalence by up to 137.1%, and reduce nonfatal and fatal opioid-involved overdoses among persons with OUD by 6.7% and 3.5%, respectively. Conclusions and Relevance In this decision analytical model study of persons with OUD, findings suggested that expansion of evidence-based interventions that directly reduce the risk of overdose fatality among persons with OUD, such as through harm reduction efforts, could engender the highest reductions in fatal overdoses in the short-term. Interventions aimed at increasing MOUD initiation and retention of persons in treatment projected considerable improvement in MOUD and OUD prevalence but could require a longer time horizon for substantial reductions in opioid-involved overdoses.
Heritability of Clinically Diagnosed Obsessive-Compulsive Disorder Among Twins
Authors: David Mataix-Cols, Lorena Fernández de la Cruz, Jan C. Beucke, Elles De Schipper, Ralf Kuja-Halkola, Paul Lichtenstein, Josep Pol-Fuster
Journal: JAMA Psychiatry (2024)

This cohort study estimates the heritability of clinically diagnosed obsessive-compulsive disorder in a sample of twins.
Metabolic Surgery for Diabetes Management
Authors: Tammy Lyn Kindel, Luke M. Funk, Amir A. Ghaferi
Journal: JAMA Surgery (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Studying Adjuvant Therapy for Hepatocellular Carcinoma
Authors: Todd J. Robinson, Allan Tsung
Journal: JAMA Surgery (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
An integrated multi-omics analysis reveals osteokines involved in global regulation
Authors: Wenquan Liang, Tiantian Wei, Le Hu, Meijun Chen, Liping Tong, Wu Zhou, Xingwei Duan, Xiaoyang Zhao, Weijie Zhou, Qing Jiang, Guozhi Xiao, Weiguo Zou, Di Chen, Zhipeng Zou, Xiaochun Bai
Journal: Cell Metabolism (2024)
Association between Fine Particulate Matter Exposure and Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease among a Cognitively Healthy Population-Based Cohort
Authors: Emma Casey, Zhenjiang Li, Donghai Liang, Stefanie Ebelt, Allan I. Levey, James J. Lah, Thomas S. Wingo, Anke Hüls
Journal: Environmental Health Perspectives (2024)

Epidemiological evidence suggests air pollution adversely affects cognition and increases the risk of Alzheimer's disease (AD), but little is known about the biological effects of fine particulate matter (PM2.5, particulate matter with aerodynamic diameter ≤2.5μm) on early predictors of future disease risk.
Combination therapy for kidney disease in people with diabetes mellitus
Authors: Daniël H. van Raalte, Petter Bjornstad, David Z. I. Cherney, Ian H. de Boer, Paola Fioretto, Daniel Gordin, Frederik Persson, Sylvia E. Rosas, Peter Rossing, Jennifer A. Schaub, Katherine Tuttle, Sushrut S. Waikar, Hiddo J. L. Heerspink
Journal: Nature Reviews Nephrology (2024)
Pre‐B acute lymphoblastic leukemia presenting with <i>NPM1</i> and <i>FLT3</i> mutations
Authors: Alesia A. Khan, Daniel James, Vibeke Andresen, Julie Atkey, Rachel Bradbury, Catherine Cargo, Richard Dillon, Bjørn Tore Gjertsen, Antony R. Goldstone, Richard Leach, Daniel Lock, Mayanka Narayanan, Nigel Russell, Eleni‐Anna Verigou, Simone Green, Adele K. Fielding, Brunangelo Falini
Journal: American Journal of Hematology (2024)

B.F. holds a patent on NPM1 mutants (number 102004901256449). The remaining authors declare no competing financial interests. All data and information concerning this study will be made available from the corresponding authors upon reasonable request.
NODAL variants are associated with a continuum of laterality defects from simple D-transposition of the great arteries to heterotaxy
Authors: Zain Dardas, Jawid M. Fatih, Angad Jolly, Moez Dawood, Haowei Du, Christopher M. Grochowski, Edward G. Jones, Shalini N. Jhangiani, Xander H. T. Wehrens, Pengfei Liu, Weimin Bi, Eric Boerwinkle, Jennifer E. Posey, Donna M. Muzny, Richard A. Gibbs, James R. Lupski, Zeynep Coban-Akdemir, Shaine A. Morris
Journal: Genome Medicine (2024)

NODAL signaling plays a critical role in embryonic patterning and heart development in vertebrates. Genetic variants resulting in perturbations of the TGF-β/NODAL signaling pathway have reproducibly been shown to cause laterality defects in humans. To further explore this association and improve genetic diagnosis, the study aims to identify and characterize a broader range of NODAL variants in a large number of individuals with laterality defects.
Insights into epileptogenesis from post-traumatic epilepsy
Authors: Matthew Pease, Kunal Gupta, Solomon L. Moshé, Daniel J. Correa, Aristea S. Galanopoulou, David O. Okonkwo, Jorge Gonzalez-Martinez, Lori Shutter, Ramon Diaz-Arrastia, James F. Castellano
Journal: Nature Reviews Neurology (2024)
Synaptic injury in the inner plexiform layer of the retina is associated with progression in multiple sclerosis
Authors: Christian Cordano, Sebastian Werneburg, Ahmed Abdelhak, Daniel J. Bennett, Alexandra Beaudry-Richard, Greg J. Duncan, Frederike C. Oertel, W. John Boscardin, Hao H. Yiu, Nora Jabassini, Lauren Merritt, Sonia Nocera, Jung H. Sin, Isaac P. Samana, Shivany Y. Condor Montes, Kirtana Ananth, Antje Bischof, Jorge Oksenberg, Roland Henry, Sergio Baranzini, Michael Wilson, Riley Bove, Richard Cuneo, Sasha Gupta, Joseph Sabatino, Joanne Guo, Simone Sacco, Nico Papinutto, Jill Hollenbach, Jeff Gelfand, Sam Pleasure, Scott Zamvil, Douglas Goodin, Emmanuelle Waubant, Refujia Gomez, Gabriel Cerono, Bardia Nourbakhsh, Stephen L. Hauser, Bruce A.C. Cree, Ben Emery, Dorothy P. Schafer, Jonah R. Chan, Ari J. Green
Journal: Cell Reports Medicine (2024)

While neurodegeneration underlies the pathological basis for permanent disability in multiple sclerosis (MS), predictive biomarkers for progression are lacking. Using an animal model of chronic MS, we find that synaptic injury precedes neuronal loss and identify thinning of the inner plexiform layer (IPL) as an early feature of inflammatory demyelination—prior to symptom onset. As neuronal domains are anatomically segregated in the retina and can be monitored longitudinally, we hypothesize that thinning of the IPL could represent a biomarker for progression in MS. Leveraging our dataset with over 800 participants enrolled for more than 12 years, we find that IPL atrophy directly precedes progression and propose that synaptic loss is predictive of functional decline. Using a blood proteome-wide analysis, we demonstrate a strong correlation between demyelination, glial activation, and synapse loss independent of neuroaxonal injury. In summary, monitoring synaptic injury is a biologically relevant approach that reflects a potential driver of progression.
A Dynamical Systems View of Psychiatric Disorders—Theory
Authors: Marten Scheffer, Claudi L. Bockting, Denny Borsboom, Roshan Cools, Clara Delecroix, Jessica A. Hartmann, Kenneth S. Kendler, Ingrid van de Leemput, Han L. J. van der Maas, Egbert van Nes, Mark Mattson, Pat D. McGorry, Barnaby Nelson
Journal: JAMA Psychiatry (2024)

Importance Psychiatric disorders may come and go with symptoms changing over a lifetime. This suggests the need for a paradigm shift in diagnosis and treatment. Here we present a fresh look inspired by dynamical systems theory. This theory is used widely to explain tipping points, cycles, and chaos in complex systems ranging from the climate to ecosystems. Observations In the dynamical systems view, we propose the healthy state has a basin of attraction representing its resilience, while disorders are alternative attractors in which the system can become trapped. Rather than an immutable trait, resilience in this approach is a dynamical property. Recent work has demonstrated the universality of generic dynamical indicators of resilience that are now employed globally to monitor the risks of collapse of complex systems, such as tropical rainforests and tipping elements of the climate system. Other dynamical systems tools are used in ecology and climate science to infer causality from time series. Moreover, experiences in ecological restoration confirm the theoretical prediction that under some conditions, short interventions may invoke long-term success when they flip the system into an alternative basin of attraction. All this implies practical applications for psychiatry, as are discussed in part 2 of this article. Conclusions and Relevance Work in the field of dynamical systems points to novel ways of inferring causality and quantifying resilience from time series. Those approaches have now been tried and tested in a range of complex systems. The same tools may help monitoring and managing resilience of the healthy state as well as psychiatric disorders.
A Dynamical Systems View of Psychiatric Disorders—Practical Implications
Authors: Marten Scheffer, Claudi L. Bockting, Denny Borsboom, Roshan Cools, Clara Delecroix, Jessica A. Hartmann, Kenneth S. Kendler, Ingrid van de Leemput, Han L. J. van der Maas, Egbert van Nes, Mark Mattson, Pat D. McGorry, Barnaby Nelson
Journal: JAMA Psychiatry (2024)

Importance Dynamical systems theory is widely used to explain tipping points, cycles, and chaos in complex systems ranging from the climate to ecosystems. It has been suggested that the same theory may be used to explain the nature and dynamics of psychiatric disorders, which may come and go with symptoms changing over a lifetime. Here we review evidence for the practical applicability of this theory and its quantitative tools in psychiatry. Observations Emerging results suggest that time series of mood and behavior may be used to monitor the resilience of patients using the same generic dynamical indicators that are now employed globally to monitor the risks of collapse of complex systems, such as tropical rainforest and tipping elements of the climate system. Other dynamical systems tools used in ecology and climate science open ways to infer personalized webs of causality for patients that may be used to identify targets for intervention. Meanwhile, experiences in ecological restoration help make sense of the occasional long-term success of short interventions. Conclusions and Relevance Those observations, while promising, evoke follow-up questions on how best to collect dynamic data, infer informative timescales, construct mechanistic models, and measure the effect of interventions on resilience. Done well, monitoring resilience to inform well-timed interventions may be integrated into approaches that give patients an active role in the lifelong challenge of managing their resilience and knowing when to seek professional help.